指南与共识泌尿生殖技术与安全MRCTPETUS

ACR适宜性标准®前列腺癌治疗前检测、监测与分期:2022年更新

ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update.
指南 / 共识 · J Am Coll Radiol · 2023-01-01

该指南由美国放射学会(ACR)多学科专家小组基于RAND/UCLA适宜性方法和GRADE证据分级制定,针对前列腺癌治疗前检测、监测与分期的影像检查适宜性进行评级。指南指出多参数MRI已成为检测、定位和评估前列腺癌局部范围的标准诊疗手段,而前列腺特异性膜抗原PET/CT和全身MRI在骨及淋巴结转移检测中应用日益增多且检出率提高。

要点

  • 多参数MRI(可联合或不联合静脉对比剂)已被确立为前列腺癌检测、定位和评估局部范围的标准诊疗手段。
  • 骨扫描和CT仍通常用于中危或高危前列腺癌患者的骨及淋巴结转移检测。
  • 前列腺特异性膜抗原PET/CT和全身MRI等新型先进影像正更频繁地用于转移检测,检出率有所提高。

核心结论

  • 前列腺癌治疗前评估的主要目标是疾病检测、定位、确定病变范围(局部和远处)及评估侵袭性,这些是复发和生存等患者结局的驱动因素。

研究设计与样本

  • ACR适宜性标准是由多学科专家小组每年审查的、针对特定临床情况的循证指南。
  • 指南制定和修订包括对同行评审期刊当前医学文献的广泛分析,并应用RAND/UCLA适宜性方法和GRADE对特定临床场景中影像和治疗程序的适宜性进行评级。
  • 在证据缺乏或模棱两可的情况下,专家意见可补充现有证据来推荐影像检查或治疗。

临床应用与阅片要点

  • 前列腺癌通常在发现血清前列腺特异性抗原水平升高或直肠指检异常后作出诊断。
  • 组织诊断通过经直肠超声引导活检或MRI靶向活检获得,通常采用多参数MRI(不联合或联合静脉对比剂)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Prostate cancer is second leading cause of death from malignancy after lung cancer in American men. The primary goal during pretreatment evaluation of prostate cancer is disease detection, localization, establishing disease extent (both local and distant), and evaluating aggressiveness, which are the driving factors of patient outcomes such as recurrence and survival. Prostate cancer is typically diagnosed after the recognizing elevated serum prostate-specific antigen level or abnormal digital rectal examination. Tissue diagnosis is obtained by transrectal ultrasound-guided biopsy or MRI-targeted biopsy, commonly with multiparametric MRI without or with intravenous contrast, which has recently been established as standard of care for detecting, localizing, and assessing local extent of prostate cancer. Although bone scintigraphy and CT are still typically used to detect bone and nodal metastases in patients with intermediate- or high-risk prostate cancer, novel advanced imaging modalities including prostatespecific membrane antigen PET/CT and whole-body MRI are being more frequently utilized for this purpose with improved detection rates. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Akin O, Woo S, Oto A, et al. ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update. J Am Coll Radiol. 2023. PMID: 37236742. doi:10.1016/j.jacr.2023.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。